Phase 2Active, not recruiting
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- Sponsor
- M.D. Anderson Cancer Center (Academic or other)
- Enrolment
- 10 enrolled
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Evolocumab; Nivolumab
- Ages
- adults, older adults
- Registry
- NCT06284564
Full record on ClinicalTrials.gov
From the registry
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
Primary outcomes
- Safety and adverse events (AEs)
History
Primary completion expected
Last registry update
Started
Registered